FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387563674> ?p ?o ?g. }

• W4387563674 abstract "To compare the proportion of participants with type 2 diabetes (T2D) treated with once-weekly (OW) subcutaneous (SC) semaglutide versus comparators who achieved a composite metabolic endpoint.SUSTAIN 1-5, 7-10 and SUSTAIN China trial data were pooled. Participants with T2D (aged ≥18 years) and glycated haemoglobin ≥7.0% (≥53 mmol/mol) who had been randomized to OW SC semaglutide (0.5 or 1.0 mg) or comparator in addition to background medication. Using patient-level data pooled by treatment, proportions of participants achieving the metabolic composite endpoint, defined as glycated haemoglobin <7% (<53 mmol/mol), blood pressure <140/90 mmHg and non-high-density lipoprotein cholesterol <130 mg/dl (<3.37 mmol/L), were evaluated following baseline adjustments. Endpoints were analysed per trial using a binomial logistic regression model with treatment, region/country and stratification factor as fixed effects and baseline value as covariate. Pooled analysis used logistic regression with treatment and trial as fixed effects and baseline value as covariate.This post hoc analysis included data from 7633 participants across 10 trials. The proportion of participants who achieved the metabolic composite endpoint was significantly higher with OW SC semaglutide 0.5 and 1.0 mg versus comparators (23.7% and 32.0% vs. 11.5%, respectively; p < .0001). Likewise, when the OW SC semaglutide doses were pooled, significantly higher proportions of patients receiving semaglutide achieved the composite metabolic endpoint versus comparators (29.1% vs. 11.4%, respectively; p < .0001).Treatment with OW SC semaglutide versus comparators was associated with increased proportions of participants with T2D meeting the composite metabolic endpoint." @default.
• W4387563674 created "2023-10-13" @default.
• W4387563674 creator A5001655356 @default.
• W4387563674 creator A5020174004 @default.
• W4387563674 creator A5027109387 @default.
• W4387563674 creator A5029775146 @default.
• W4387563674 creator A5036949656 @default.
• W4387563674 creator A5037989560 @default.
• W4387563674 creator A5048520696 @default.
• W4387563674 creator A5071232347 @default.
• W4387563674 creator A5073949429 @default.
• W4387563674 creator A5082525611 @default.
• W4387563674 date "2023-10-12" @default.
• W4387563674 modified "2023-10-13" @default.
• W4387563674 title "Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from <scp>SUSTAIN</scp> 1‐5, 7‐10 and <scp>SUSTAIN</scp> China" @default.
• W4387563674 cites W2023329893 @default.
• W4387563674 cites W2116239162 @default.
• W4387563674 cites W2139634859 @default.
• W4387563674 cites W2462710388 @default.
• W4387563674 cites W2572398654 @default.
• W4387563674 cites W2602700371 @default.
• W4387563674 cites W2604469807 @default.
• W4387563674 cites W2774157762 @default.
• W4387563674 cites W2787255324 @default.
• W4387563674 cites W2801715295 @default.
• W4387563674 cites W2908132154 @default.
• W4387563674 cites W2908397509 @default.
• W4387563674 cites W2918407168 @default.
• W4387563674 cites W2973758715 @default.
• W4387563674 cites W2974008202 @default.
• W4387563674 cites W3004369106 @default.
• W4387563674 cites W3093123473 @default.
• W4387563674 cites W3166972534 @default.
• W4387563674 cites W3172134520 @default.
• W4387563674 cites W4200355173 @default.
• W4387563674 cites W4211265378 @default.
• W4387563674 cites W4225343866 @default.
• W4387563674 cites W4296802076 @default.
• W4387563674 cites W4311254382 @default.
• W4387563674 doi "https://doi.org/10.1111/dom.15309" @default.
• W4387563674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37822270" @default.
• W4387563674 hasPublicationYear "2023" @default.
• W4387563674 type Work @default.
• W4387563674 citedByCount "0" @default.
• W4387563674 crossrefType "journal-article" @default.
• W4387563674 hasAuthorship W4387563674A5001655356 @default.
• W4387563674 hasAuthorship W4387563674A5020174004 @default.
• W4387563674 hasAuthorship W4387563674A5027109387 @default.
• W4387563674 hasAuthorship W4387563674A5029775146 @default.
• W4387563674 hasAuthorship W4387563674A5036949656 @default.
• W4387563674 hasAuthorship W4387563674A5037989560 @default.
• W4387563674 hasAuthorship W4387563674A5048520696 @default.
• W4387563674 hasAuthorship W4387563674A5071232347 @default.
• W4387563674 hasAuthorship W4387563674A5073949429 @default.
• W4387563674 hasAuthorship W4387563674A5082525611 @default.
• W4387563674 hasBestOaLocation W43875636741 @default.
• W4387563674 hasConcept C105795698 @default.
• W4387563674 hasConcept C119043178 @default.
• W4387563674 hasConcept C126322002 @default.
• W4387563674 hasConcept C134018914 @default.
• W4387563674 hasConcept C142724271 @default.
• W4387563674 hasConcept C151956035 @default.
• W4387563674 hasConcept C168563851 @default.
• W4387563674 hasConcept C203092338 @default.
• W4387563674 hasConcept C204787440 @default.
• W4387563674 hasConcept C27081682 @default.
• W4387563674 hasConcept C2777180221 @default.
• W4387563674 hasConcept C2781308992 @default.
• W4387563674 hasConcept C2909862629 @default.
• W4387563674 hasConcept C33923547 @default.
• W4387563674 hasConcept C555293320 @default.
• W4387563674 hasConcept C67761136 @default.
• W4387563674 hasConcept C71924100 @default.
• W4387563674 hasConceptScore W4387563674C105795698 @default.
• W4387563674 hasConceptScore W4387563674C119043178 @default.
• W4387563674 hasConceptScore W4387563674C126322002 @default.
• W4387563674 hasConceptScore W4387563674C134018914 @default.
• W4387563674 hasConceptScore W4387563674C142724271 @default.
• W4387563674 hasConceptScore W4387563674C151956035 @default.
• W4387563674 hasConceptScore W4387563674C168563851 @default.
• W4387563674 hasConceptScore W4387563674C203092338 @default.
• W4387563674 hasConceptScore W4387563674C204787440 @default.
• W4387563674 hasConceptScore W4387563674C27081682 @default.
• W4387563674 hasConceptScore W4387563674C2777180221 @default.
• W4387563674 hasConceptScore W4387563674C2781308992 @default.
• W4387563674 hasConceptScore W4387563674C2909862629 @default.
• W4387563674 hasConceptScore W4387563674C33923547 @default.
• W4387563674 hasConceptScore W4387563674C555293320 @default.
• W4387563674 hasConceptScore W4387563674C67761136 @default.
• W4387563674 hasConceptScore W4387563674C71924100 @default.
• W4387563674 hasLocation W43875636741 @default.
• W4387563674 hasLocation W43875636742 @default.
• W4387563674 hasOpenAccess W4387563674 @default.
• W4387563674 hasPrimaryLocation W43875636741 @default.
• W4387563674 hasRelatedWork W2757046241 @default.
• W4387563674 hasRelatedWork W2763339077 @default.
• W4387563674 hasRelatedWork W2889742409 @default.
• W4387563674 hasRelatedWork W2920262859 @default.
• W4387563674 hasRelatedWork W3033586845 @default.
• W4387563674 hasRelatedWork W3180244763 @default.

• next